Tian Mei

Director of the Center for Global Collaboration Promotion at Fudan University; and Academic Leader of the Nuclear Medicine/PET Center at Huashan Hospital Affiliated to Fudan University. She is a Distinguished Dr. of the "Changjiang Scholars Program" of the Ministry of Education and a recipient of the National Science Fund for Distinguished Young Scholars. She was the first Chinese president of the World Molecular Imaging Society (WMIS) since its inception and is the Vice President of the Chinese Society for Cognitive Science. During her time at Harvard Medical School, she was deeply involved in the Phase I and II clinical trials of Gleevec, using PET molecular imaging for systemic lesion localization and early efficacy assessment. She led the first major project in the field of nuclear medicine funded by the National Natural Science Foundation of China, "Precision Diagnosis and Treatment of Neurodegenerative Diseases using Nuclear Medicine." In 2018, Dr. Tian Mei led a multidisciplinary team composed of imaging, pediatrics, and neurosurgery and neurology specialists to successfully achieve intracranial biochemical metabolism and receptor function imaging in epilepsy patients, significantly increasing the detection rate of epileptogenic foci in non-surgical epilepsy children from 15% using traditional clinical methods. She pioneered the establishment of China's first nuclear medicine disease database and quantitative software development platform for neuropsychiatric diseases. Specializes in the precise diagnosis of epilepsy, Alzheimer's disease, Parkinson's disease, and malignant tumors using PET imaging. Serves as associate editor of *JNM* and *EJNMMI*, associate editor of the 9th edition of the *Nuclear Medicine* textbook, and editor-in-chief of the 10th edition. Recipient of honors including the China Youth May Fourth Medal, the China Young Female Scientist Award, and the National March 8th Red Banner Pacesetter Award.